8 hours ago
1
fermate/iStock via Getty Images
Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced Wednesday that it expects its partner Sarepta Therapeutics (NASDAQ:SRPT), which recently withdrew its gene therapy Elevidys from the U.S. market, will meet financial obligations required under a 2025 licensing agreement between the two companies.
Sarepta (
English (US) ·